SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Sichuan Biokin Unit Receives $250 Million Milestone Payment from Bristol Myers Squibb

Sichuan Biokin Pharmaceutical says its unit received the second milestone payment under the Iza-Bren agreement.

BMY

Related stories